General Information of DTT (ID: TT2A0DR)

DTT Name Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A) DTT Info
Gene Name SRD5A1

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Discontinued Drug(s)
Approved Drug(s)
Clinical Trial Drug(s)
4 Approved Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Azelaic Acid DMHVL0J Acne vulgaris ED80 Approved [1]
Dutasteride DMQ4TJK Benign prostatic hyperplasia GA90 Approved [2]
Finasteride DMWV3TZ Baldness, male pattern Approved [2]
Polyestradiol Phosphate DM0PMGJ Prostate cancer 2C82.0 Approved [3]
------------------------------------------------------------------------------------
5 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dutasteride + tamsulosin DM6P8HU Benign prostatic hyperplasia GA90 Phase 3 [4]
Epristeride DM35T1O Hirsutism ED72 Phase 3 [5]
FK-143 DMEL15U Prostate disease GA91 Phase 2 [6]
Turosteride DMW7PFS Prostate disease GA91 Phase 2 [7]
IZONSTERIDE DM3KXMG Hirsutism ED72 Phase 1/2 [8]
------------------------------------------------------------------------------------
5 Discontinued Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
ONO-3805 DM1RKWV Prostate disease GA91 Discontinued in Phase 3 [9]
CS-891B DM17I8O Alopecia ED70 Discontinued in Phase 2 [10]
MK-0963 DMNAJGK Prostate disease GA91 Discontinued in Phase 1 [11]
MK-434 DMERKWM Prostate disease GA91 Discontinued in Phase 1 [12]
GI-197111 DM6HZU1 Alopecia ED70 Terminated [13]
------------------------------------------------------------------------------------
Molecule Interaction Atlas

References

1 Inhibition of 5 alpha-reductase activity in human skin by zinc and azelaic acid. Br J Dermatol. 1988 Nov;119(5):627-32.
2 The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme Can Urol Assoc J. 2009 Jun;3(3 Suppl 2):S109-14.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
5 Discovery of a novel hybrid from finasteride and epristeride as 5alpha-reductase inhibitor. Bioorg Med Chem Lett. 2011 Jan 1;21(1):475-8.
6 FK143, a novel nonsteroidal inhibitor of steroid 5 alpha-reductase: (1) In vitro effects on human and animal prostatic enzymes. J Steroid Biochem Mol Biol. 1995 Apr;52(4):357-63.
7 Hormonal effects of turosteride, a 5 alpha-reductase inhibitor, in the rat. J Steroid Biochem Mol Biol. 1993 Nov;46(5):549-55.
8 Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible... Urology. 2004 Jan;63(1):114-9.
9 Significant role of 5 alpha-reductase on feedback effects of androgen in rat anterior pituitary cells demonstrated with a nonsteroidal 5 alpha-redu... J Androl. 1994 Nov-Dec;15(6):521-7.
10 The novel drug CS-891 inhibits 5alpha-reductase activity in freshly isolated dermal papilla of human hair follicles. Eur J Dermatol. 2000 Dec;10(8):593-5.
11 Pharmacodynamics of MK-0963, a new 5 alpha-reductase inhibitor: effects on serum androgen concentrations. Clin Pharmacol Ther. 1994 Jan;55(1):50-4.
12 The effects of progesterone, 4,16-androstadien-3-one and MK-434 on the kinetics of pig testis microsomal testosterone-4-ene-5alpha-reductase activity. J Steroid Biochem Mol Biol. 1997 Mar;60(5-6):353-9.
13 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008867)